Valeant says can contain hit to dermatology, projects 2016 growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Upward Earnings Revisions to Drive Valeant (VRX) Higher - Guggenheim
December 17, 2015 7:13 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $195 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's analyst day. The analyst thinks upwards consensus earnings revisions and multiple expansion will drive VRX shares higher
Chen commented, "Post VRX's Investor Day on 12/16/15, we think upwards... More
